Screen Shot 2018-03-21 at 2.03.13 PM

PCSK9 Inhibitor Therapeutics 2018: Analyses of Specific Patient Populations Data

http://academiccme.com/wp-content/uploads/2018/03/Screen-Shot-2018-03-21-at-2.03.13-PM.png

Course Information

Therapautic Area: Cardiology
Format(s): Webcast
Credit(s): 1.00 AMA PRA Category 1 Credits™; 1.0 CNE Contact Hour
Activity Dates: April 16, 2018 - April 15, 2019

 

Program Overview

This educational program will explore and analyze data for PCSK9 inhibitor therapeutics in specific patient populations. Expert faculty will relay updates regarding recent PCSK9 inhibitor data and dive into how to optimally apply these therapies into clinical practice. Recent dyslipidemia guidelines will also be reviewed. The panel will discuss how to best improve outcomes for dyslipidemia patients, including those with stroke or at high CV risk.

Target Audience

Cardiologists, internists, nurse practitioners, nurses and other healthcare professionals involved in the management of patients with dyslipidemia

Educational Objectives

  1. Explain the most recent subset data for outcomes trials concerning PCSK9 inhibitors
  2. Apply recent dyslipidemia guidelines and optimal PCSK9 inhibitors into clinical practice
  3. Incorporate recent PCSK9 inhibitor data to improve outcomes for dyslipidemia patients with stroke or at high CV risk
  4. Discuss strategies to improve knowledge, skills, or performance of the healthcare team

Faculty

Brown HeadshotAlan S. Brown, MD
Director, Division of Cardiology
Advocate Lutheran General Hospital
Park Ridge, Illinois

 

 

BrintonEliotEliot A. Brinton, MD, FAHA, FNLA
Past President, American Board of Clinical Lipidology
President, Utah Lipid Center
Salt Lake City, Utah
 
 
—–

Underberg #6 James A. Underberg, MD, MS 
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, New York
saseen_joe_14_206_2Joseph J. Saseen, PharmD, CLS, FNLA 
Professor
Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, Colorado

—-

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Relationship Identified With:
Alan S. Brown, MD Consultant/Advisor: Akcea Therapeutics; Amgen Inc.; Kastle Therapeutics; Kowa Pharmaceuticals America, Inc.; Merck; Regeneron PharmaceuticalsSpeaker’s Bureau: Amgen Inc.; Kowa Pharmaceuticals America, Inc.; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLC
Eliot A. Brinton, MD Consultant/Advisor: Akcea Therapeutics; Amarin Pharma Inc.; Balchem; Kowa Pharmaceuticals America, Inc.; Merck; PTS Diagnostics; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCSpeaker Bureau: Akcea Therapeutics; Amarin Pharma Inc; Boehringer-Ingelheim; Kowa Pharmaceuticals America, Inc.; Merck; Novo Nordisk A/S; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLC
Joseph J. Saseen, PharmD, CLS  Nothing to disclose
James A. Underberg, MD, MS  Consultant/Advisor: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Invitae Corporation; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCSpeaker’s Bureau: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCGrant/Research Support: Aegerion Pharmaceuticals, Inc.; Pfizer

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Gilmartin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hours (1.0 CNE pharmacotherapeutic contact hour).

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Eisai Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CME Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by: 68151cf1-f976-429e-b78e-bc0618e6d2a5NLA_2018_CLUSanAntonio_Logo_Vert_Print